Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Provides Update on Beacon Mill Restart and Exploration Updates (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AMRN)

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

GlobeNewswire 2 days ago

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

GlobeNewswire 9 days ago

Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 

GlobeNewswire 9 days ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

GlobeNewswire February 27, 2025

Amarin Receives National Reimbursement for VAZKEPA® in Austria

GlobeNewswire February 25, 2025

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

GlobeNewswire February 19, 2025

Amarin Receives National Reimbursement for VAZKEPA® in Italy

GlobeNewswire December 16, 2024

Amarin Appoints Peter Fishman Chief Financial Officer

GlobeNewswire December 13, 2024

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions

GlobeNewswire November 11, 2024
View More News ››

Opinion & Analysis (NDAQ:AMRN)

Krill oil boom is real

Andrew Mickey June 3, 2011
View More Opinion ››

Bullboard Posts (NDAQ:AMRN)

Amarin Reports Fourth Quarter Financial Results&#xA0;& Busin

BREAKING NEWS: $AMRN Amarin Reports Fourth Quarter Financial Results&#xA0;& Business Update&#xA0;and Announces Important...
whytestocks - 9 days ago

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Tinekerensen - April 13, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
Tinekerensen - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
Tinekerensen - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
Tinekerensen - June 2, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Tinekerensen - May 11, 2022
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. is a Canada-based uranium developer. The Company is engaged in the acquisition, exploration and ...
View More »